Synapse - Robert Motzer

Results (1247)

Changes, challenges and opportunities in cancer care during the COVID-19 era and beyond: Building on lessons learned from the pandemic

Review

Motzer, R. J.; Jonasch, E. A.; McGregor, B. A.; Figlin, R. A.
Kidney Cancer Journal (2021)

Fulltext@MSK | Save

Сохраненное время качественной жизни, проведенное без клинических симптомов и проявлений токсичности (Q-TWiST), при лечении комбинацией ленватиниба и эверолимуса по сравнению с монотерапией эверолимусом у пациентов с распространенным почечно-клеточным раком

Journal Article

Lee, C. H.; Wan, Y.; Smith, A.; Xie, R.; Motzer, R. J.
Onkourologiya (2021)

Fulltext@MSK | Save

Post hoc analysis of the CLEAR study in advanced renal cell carcinoma (RCC): Effect of subsequent therapy on survival outcomes in the lenvatinib (L) plus everolimus (E) vs sunitinib (S) treatment arms

Meeting Abstract

Grünwald, V.; Hutson, T.; Choueiri, T. K.; Motzer, R.; Rha, S. Y.; Alyasova, A.; Merchan, J.; Gurney, H.; Peer, A.; Takagi, T.; more...
Oncology Research and Treatment (2021)

Fulltext@MSK | Save

Analysis of the CLEAR study in patients (pts) with advanced renal cell carcinoma (RCC): Depth of response and efficacy for selected subgroups in the lenvatinib (L) plus pembrolizumab (P) and sunitinib (S) treatment arms

Meeting Abstract

Grünwald, V.; Powles, T.; Kopyltsov, E.; Kozlov, V.; Alonso, G. T.; Eto, M.; Hutson, T.; Motzer, R.; Winquist, E.; Maroto, P.; more...
Oncology Research and Treatment (2021)

Fulltext@MSK | Save

Nivolumab plus cabozantinib (N plus C) vs sunitinib (S) for advanced renal cell carcinoma (aRCC): Outcomes by baseline disease characteristics in the phase 3 CheckMate 9ER trial

Meeting Abstract

Bedke, J.; Powles, T.; Burotto, M.; Bourlon, M. T.; Hsieh, J. J.; Basso, U.; Shah, A. Y.; Suarez, C.; Porta, C.; Barrios, C.; more...
Oncology Research and Treatment (2021)

Fulltext@MSK | Save

Germline variants identified in patients with early-onset renal cell carcinoma referred for germline genetic testing

Journal Article

Truong, H.; Sheikh, R.; Kotecha, R.; Kemel, Y.; Reisz, P. A.; Lenis, A. T.; Mehta, N. N.; Khurram, A.; Joseph, V.; Mandelker, D.; more...
European Urology Oncology (2021)

Fulltext@MSK | Save

Treatment-free survival after immune checkpoint inhibitor therapy versus targeted therapy for advanced renal cell carcinoma: 42-month results of the CheckMate 214 trial

Journal Article

Regan, M. M.; Jegede, O. A.; Mantia, C. M.; Powles, T.; Werner, L.; Motzer, R. J.; Tannir, N. M.; Lee, C. H.; Tomita, Y.; Voss, M. H.; more...
Clinical Cancer Research (2021)

Fulltext@MSK | Save

Nivolumab plus cabozantinib (N+C) versus sunitinib (S) for advanced renal cell carcinoma (aRCC): Outcomes by baseline disease characteristics in the phase 3 CheckMate 9ER trial

Meeting Abstract

Apolo, A. B.; Powles, T.; Burotto, M.; Bourlon, M. T.; Hsieh, J. J.; Basso, U.; Shah, A. Y.; Suarez, C.; Porta, C.; Barrios, C. H.; more...
Journal of Clinical Oncology (2021)

Fulltext@MSK | Save

CANTATA: Primary analysis of a global, randomized, placebo (Pbo)-controlled, double-blind trial of telaglenastat (CB-839) + cabozantinib versus Pbo + cabozantinib in advanced/metastatic renal cell carcinoma (mRCC) patients (pts) who progressed on immune checkpoint inhibitor (ICI) or anti-angiogenic therapies

Meeting Abstract

Tannir, N. M.; Agarwal, N.; Porta, C.; Lawrence, N. J.; Motzer, R. J.; Lee, R. J.; Jain, R. K.; Davis, N. B.; Appleman, L. J.; Goodman, O. B.; more...
Journal of Clinical Oncology (2021)

Fulltext@MSK | Save

Analysis of the CLEAR study in patients (pts) with advanced renal cell carcinoma (RCC): Depth of response and efficacy for selected subgroups in the lenvatinib (LEN) + pembrolizumab (PEMBRO) and sunitinib (SUN) treatment arms

Meeting Abstract

Grünwald, V.; Powles, T.; Kopyltsov, E.; Kozlov, V.; Gordoa, T. A.; Eto, M.; Hutson, T. E.; Motzer, R. J.; Winquist, E.; Maroto-Rey, P.; more...
Journal of Clinical Oncology (2021)

Fulltext@MSK | Save